QXO (NYSE:QXO) has entered into a definitive agreement to acquire TopBuild (NYSE:BLD), North America’s largest distributor and installer of insulation and related building products, in a transaction valued at approximately $17 billion.
Peoples Bancorp of North Carolina (NASDAQ:PEBK), the parent company of Peoples Bank, today reported financial results for the first quarter ended March 31, 2026.
ANI Pharmaceuticals (NASDAQ:ANIP) announced today the U.S. Food and Drug Administration (FDA) approval and commercial launch of Pimozide Tablets in 1 mg and 2 mg strengths.
Pfizer (NYSE:PFE) and Astellas announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for the perioperative use of Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).
Digi Power X (NASDAQ:DGXX) announced today that it has signed a 24-month bare metal GPU rental agreement with SubQ AI, a move that formally validates the commercial launch of its proprietary NeoCloudz infrastructure.
NANO-X IMAGING (NASDAQ:NNOX), an innovative medical imaging technology company, today reported financial results for the fourth quarter ended December 31, 2025.
MainStreet Bancshares (NASDAQ:MNSB), the holding company for MainStreet Bank, today reported net income of $4.1 million, or $0.48 per diluted common share, for the quarter ended March 31, 2026.
YY Group Holding (NASDAQ:YYGH), a data-driven human resources and business process outsourcing provider, today reported its unaudited financial results for the fiscal year ended December 31, 2025.
QuidelOrtho (NASDAQ:QDEL), a global powerhouse in in vitro diagnostics, has announced the acquisition of LEX Diagnostics.
AstraZeneca (NASDAQ:AZN) today announced positive high-level results from its pivotal Phase III MIRANDA trial, evaluating tozorakimab as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.
Capital City Bank Group (NASDAQ:CCBG) today reported financial results for the first quarter ended March 31, 2026, delivering a consistent performance characterized by disciplined expense management and improved capital metrics.
-640x360.webp&w=3840&q=75)
